211915-06-9

• 常用中文名：达比加群酯
• 常用英文名：Dabigatran etexilate
• CAS号：211915-06-9
• 分子式：C₃₄H₄₁N₇O₅
• 分子量：627.733
• 相关类别： 原料药 血液系统用药 抗凝血药及抗血小板药
• 发布时间：2018-06-05 08:00:00
• 更新时间：2026-08-02 21:08:47
• Dabigatran etexilate(BIBR-1048)是口服活性的dabigatran原药,是可逆的直接凝血酶抑制剂(DTI),Ki为4.5 nM。

名称

• 中文名: 达比加群酯
• 英文名: dabigatran etexilate
• 中文别名: 3-(2-(((4-(N-((己基氧基)羰基)氨基甲酰基)苯基)氨基)甲基)-1-甲基-N-(吡啶-2-基)-1H-苯并[D]咪唑-5-甲酰胺基)丙酸乙酯; 达比甲群酯; 达比加群酯中间体(DBJQ-F) BIBR; 达比加群酯杂质(全套); ETEXILATE达比加群; Dabigatran (BIBR-1048) etexilate :达比加群酯; 达比加群酯API; 甲磺酸达比加群酯系列; 重组 Mouse ED/DL蛋白 (Fc标签)-PKSM041006; 甲磺酸达比加群-中间体3; 达比加群酯,10 MM DMSO 溶液; 达比加群酯自由碱(达比加群酯); 达比加群酯游离碱; 达比加群酯杂质67; Dabigatran etexilate试剂; 甲磺酸达比加群酯中间体3; 达比加群酯自由碱; 原研代码CDBA510BS; 达比加群中间体DB-8; 达比加群酯杂质; 3-[[[2-[[[4-[[[( 己氧基) 羰基] 氨基] 亚氨甲基] 苯基] 氨基] 甲基]-1- 甲基-1H- 苯并咪唑-5-基] 羰基]( 吡啶-2- 基) 氨基] 丙酸乙酯; 达比加群酯P-1; CAS编号:211-9; BIBR-1048 5mg试剂; N-[[2-[[[4-[[[(己氧基)羰基]氨基]亚氨甲基]苯基]氨基]甲基]-1-甲基-1H-苯并咪唑-5-基]羰基]-N-2-吡啶-Β-氨基,丙酸乙酯; 达比加群酯-[13C6]/精确称量; N-[[2-[[[4-[[[(己氧基)羰基]氨基]亚氨基甲基]苯基]氨基]甲基]-1-甲基-1H-苯并咪唑-5-基]羰基]-N-2-吡啶基-Β-丙氨酸乙酯; 直接凝血酶抑制剂(DABIGATRAN ETEXILATE); N-[2-[4-[N-(己氧基羰基)氨基]苯氨基甲基]-1-甲基-1H-苯并咪唑-5-基羰基]-N-(2-吡啶)-BETA-丙氨酸乙酯; 特比加群酯; 抗体:DABIGATRAN ETEXILATE ANTIBODY (SAA0560) RGK09701; N-[[2-[[[4-[[[(己氧基)羰基]氨基]亚氨甲基]苯基]氨基]甲基]-1-甲基-1H-苯并咪唑-5-基]羰基]-N-(2-吡啶)-Β-丙氨酸乙酯; 抑制剂Dabigatran etexilate
• 英文别名: BIBR-1048MS; Etexilate; Dabigatran etexilate （Mesylat）; N-[2-[4-[N-(Hexyloxycbonyl)amidino]phenylaminomethyl]-1-methyl-1H-benzimidazol-5-ylcbonyl]-N-(2-pyridyl)-beta-alanine ethyl ester(Dabigatran etexilate); N-[2-[4-[N-(Hexyloxycbonyl)aMidino]phenylaMinoMethyl]-1-Methyl-1H-benziMidazol-5-ylcbonyl]-N-(2; Dabigatran (BIBR-1048) etexilate; Rendix; Dabigatran etexilate, 10 mM in DMSO; ethyl 3-(2-(((4-(N-((hexyloxy)carbonyl)cbamimidoyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-cboxamido)propanoate; DBG-3A/DBG-3 (DABIGATRAN IMPURITY); BIBR-1048(Dabigatran etexilate); Dabigatran etexilate (Dabigatran etexilate methanesulfonate); Ethyl N-[[2-[[4-[N-[(Hexyloxy)carbonyl]cbamimidoyl]anilino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-beta-alaninate; abigatranetexilate; Ethyl 3-(((2-(((4-(((( hexyloxy)carbonyl)amino)iminomethyl)pheny l)amino)methyl)-1-methy-lH-benzimidazole-5- yl)carbonyl)(pyridin-2-yl)amino)propanoate; Dabigatran etexilate; Pradaxa; Dabigatran Etexilate (free base); Dabigatran etexilate impurity1516; BIBR-1048; β-Alanine, N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-, ethyl ester; N-[[2-[[[4-[[[(Hexyloxy)carbonyl]aMidino]iMinoMethyl]phenyl]amino]Methyl]-1-Methyl-1H-benziMidazol-5-yl]carbonyl]-N-2-pyridyl-beta-alanine,ethyl ester; Dabigatran EtexilateQ: What is Dabigatran Etexilate Q: What is the CAS Number of Dabigatran Etexilate Q: What is the storage condition of Dabigatran Etexilate Q: What e the applications of Dabigatran Etexilate; Dabigatranetexilatebase; Dabigatron; (E)-ethyl 3-(2-((4-(N'-(hexyloxycbonyl)cbamimidoyl)phenylamino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-cboxamido)propanoate; phenol red sodium salt; Dabigatran etexilate - Bio-X; Dabigatran Free Base; Dabigatran Etexilate N-[[2-[[[4- [[[(Hexyloxy)carbonyl]amino]iminomethyl]phenyl]amino]methy l]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-β- Alanine Ethyl Ester; Prazaxa; Ethyl 3-(2-((4-(N-(hexyloxycbonyl)cbamimidoyl)phenylamino)methyl)-1-methyl-N-(pyridin-2-yl; Hexyl 2-(4-(((5-((3-ethoxy-3-oxopropyl)(pyridin-2-yl)cbamoyl)-1-methyl-1H-benzo[d]imidazol-2-yl)methyl)amino)benzylidene)hydrazinecboxylate; phenolsulfonphthalein sodium salt; Pradax; phenolsulphophthaleine sodium salt; N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-β-Alanine, ethyl ester; N-[2-[4-[N-(Hexyloxycbonyl)amidino]phenylaminomethyl]-1-methyl-1H-benzimidazol-5-ylcbonyl]-N-(2-pyridyl)-beta-alanine ethyl ester; Alanine, N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iMinoMethyl]phenyl]amino]Methyl]-1-Methyl-1H-benziMidazol-5-yl]carbonyl]-N-2-pyridinyl-, ethyl ester; BIBR-1048, >=; Ethyl 3-[2-[[[4-[N-[(Hexyloxy)carbonyl]cbamimidoyl]phenyl]amino]methyl]-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidaz; BIBR 1048; DABIGATRAN ETEXILATE;BIBR1048; Ethyl 3-{[(2-{[(4-{N'-[(Hexyloxy) carbonyl] cbamimidoyl} phenyl) amino]methyl}-l-methyl- lH-benzimidazol-5-yl)carbonyl] (2- pyridinyl)amino} propanoate; ethyl 3-[[2-[[4-[(Z)-N'-hexoxycbonylcbamimidoyl]anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate; Dabigatran etexilate //BP; Ethyl 3-(((2-(((4-((((hexyloxy) carbonyl) amino) iminomethyl) phenyl) amino)\methyl)-1-methyl-1H-benzimidazol-5-yl)carbonyl)(pyridin-2-yl)amino) propanoate; phenolsulfonephthalein sodium; DABIGATRAN ETEXILATE , W/W PELLETS; 3- (3- (2- (4-cyanoaniline) acetamido) -4- (methylamino) - N - (pyridin-2-yl) benzamido) propionic acid ethyl ester; BIBR-1048 (Dabigatran); N-[2-[4-[N-(Hexyloxycbonyl)amidino]phenylaminomethyl]-1-me; Pradaxa (dabigatran); PR sodium salt; Dabigatran Etexilatr; (5-bromo-2-methylphenyl)(5-(4-fluorophenyl)thiophen-2-yl)methanone (Intermediate of Canagliflozin); Ethyl N-[(2-{[(4-{N-[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1H-benzimidazol-5-yl)carbonyl]-N-2-pyridinyl-β-alaninate; Dabigatran ester; 1-methyl-2-[N-[4-(-n-hexyloxycbonylamidino) phenyl]aminomethyl]benzimidazol-5-yl- cboxylicacid-N-(2-pyridyl)-N- (2-ethoxycbonylethyl)amide; Dabigatran P-1; PHENOL RED,ACS

物化性质

• 密度: 1.2±0.1 g/cm3
• 沸点: 827.9±75.0 °C at 760 mmHg
• 熔点: 128-129°
• 分子式: C₃₄H₄₁N₇O₅
• 分子量: 627.733
• 闪点: 454.5±37.1 °C
• 精确质量: 627.316895
• PSA: 154.03000
• LogP: 5.13
• 蒸汽压: 0.0±3.0 mmHg at 25°C
• 折射率: 1.615
• 储存条件: 2~8℃

生物活性

• 描述: Dabigatran etexilate(BIBR-1048)是口服活性的dabigatran原药,是可逆的直接凝血酶抑制剂(DTI),Ki为4.5 nM。
• 相关类别:
  信号通路 >> 代谢酶/蛋白酶 >> 凝血酶
  研究领域 >> 心血管疾病
• 参考文献:

  [1]. Wienen W, Stassen JM, Priepke H, In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally activeprodrug, dabigatran etexilate. Thromb Haemost. 2007 Jul;98(1):155-62.

  [2]. Kansal AR, Sorensen SV, Gani R, Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients withatrial fibrillation. Heart. 2012 Apr;98(7):573-8.

MSDS

Material Safety Data Sheet Section1. Identification of the substance Product Name: Dabigatran etexilate Synonyms: Section2. Hazards identification Harmful by inhalation, in contact with skin, and if swallowed. Section3. Composition/information on ingredients. Ingredient name:Dabigatran etexilate CAS number:211915-06-9 Section4. First aid measures Skin contact:Immediately wash skin with copious amounts of water for at least 15 minutes while removing contaminated clothing and shoes. If irritation persists, seek medical attention. Eye contact:Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical attention. Inhalation:Remove to fresh air. In severe cases or if symptoms persist, seek medical attention. Ingestion:Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention. Section5. Fire fighting measures In the event of a fire involving this material, alone or in combination with other materials, use dry powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus should be worn. Section6. Accidental release measures Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national standards. Respiratory precaution:Wear approved mask/respirator Hand precaution:Wear suitable gloves/gauntlets Skin protection:Wear suitable protective clothing Eye protection:Wear suitable eye protection Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container for disposal. See section 12. Environmental precautions: Do not allow material to enter drains or water courses. Section7. Handling and storage Handling:This product should be handled only by, or under the close supervision of, those properly qualified in the handling and use of potentially hazardous chemicals, who should take into account the fire, health and chemical hazard data given on this sheet. Storage:Store in closed vessels, refrigerated. Section8. Exposure Controls / Personal protection Engineering Controls: Use only in a chemical fume hood. Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles. General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse. Section9. Physical and chemical properties Appearance:Not specified Boiling point:No data Melting point:No data Flash point:No data Density:No data Molecular formula: C34H41N7O5 Molecular weight: 627.7 Section10. Stability and reactivity Conditions to avoid: Heat, flames and sparks. Materials to avoid: Oxidizing agents. Possible hazardous combustion products: Carbon monoxide, nitrogen oxides. Section11. Toxicological information No data. Section12. Ecological information No data. Section13. Disposal consideration Arrange disposal as special waste, by licensed disposal company, in consultation with local waste disposal authority, in accordance with national and regional regulations. Section14. Transportation information Non-harzardous for air and ground transportation. Section15. Regulatory information No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302, or have known CAS numbers that exceed the threshold reporting levels established by SARA Title III, Section 313. SECTION 16 - ADDITIONAL INFORMATION N/A

安全

• 危害码 (欧洲): Xi
• 海关编码: 2933990090

合成路线

上下游产品

上游产品  7
10185-68-9 1411034-21-3 1411034-23-5 1411034-25-7
42288-26-6 212322-56-0 211915-84-3
下游产品  1
872728-81-9

海关

海关编码	2933990090
中文概述	2933990090. 其他仅含氮杂原子的杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%
申报要素	品名, 成分含量, 用途, 乌洛托品请注明外观, 6－己内酰胺请注明外观, 签约日期
Summary	2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%